Akorn (AKRX - Get Report) has announced that its Akorn-Strides joint venture has entered into a new agreement with Pfizer (PFE - Get Report) in which it will receive $35 million in cash for 16 abbreviated new drug approvals.
Shares of Akorn are up 1.1%, or 7 cents, to $6.46 in premarket trading.
Pfizer's animal health unit says it will acquire Synbiotics, a provider of laboratory diagnostic products for the animal health care industry. The acquisition is expected to close later this week.
Pfizer shares are up 0.28%, or 5 cents, to $17.65 in premarket trading.
Impax Laboratories (IPXL - Get Report) announced yesterday that the U.S. Food and Drug Administration has granted the company final approval for the generic version of Doryx, a drug used to treat bacterial infection, in 75 and 100 milligram tablets. Shares of the company are up 0.15%, or 3 cents, to $20.54 in premarket trading.
-- Written by Theresa McCabe in Boston.
>To contact the writer of this article, click here: Theresa McCabe. >To follow the writer on Twitter, go to @TheresaMcCabe. >To submit a news tip, send an email to: firstname.lastname@example.org.